Cargando…
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
Immune checkpoint inhibitors (ICIs) such as anti-PD-L1 antibodies are widely used to treat human cancers, and growing evidence suggests that ICIs are promising treatments for canine malignancies. However, only some canine oral malignant melanoma (OMM) cases respond to ICIs. To explore biomarkers pre...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166720/ https://www.ncbi.nlm.nih.gov/pubmed/35665759 http://dx.doi.org/10.1038/s41598-022-13484-8 |
_version_ | 1784720667752529920 |
---|---|
author | Maekawa, Naoya Konnai, Satoru Asano, Yumie Sajiki, Yamato Deguchi, Tatsuya Okagawa, Tomohiro Watari, Kei Takeuchi, Hiroto Takagi, Satoshi Hosoya, Kenji Kim, Sangho Ohta, Hiroshi Kato, Yukinari Suzuki, Yasuhiko Murata, Shiro Ohashi, Kazuhiko |
author_facet | Maekawa, Naoya Konnai, Satoru Asano, Yumie Sajiki, Yamato Deguchi, Tatsuya Okagawa, Tomohiro Watari, Kei Takeuchi, Hiroto Takagi, Satoshi Hosoya, Kenji Kim, Sangho Ohta, Hiroshi Kato, Yukinari Suzuki, Yasuhiko Murata, Shiro Ohashi, Kazuhiko |
author_sort | Maekawa, Naoya |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) such as anti-PD-L1 antibodies are widely used to treat human cancers, and growing evidence suggests that ICIs are promising treatments for canine malignancies. However, only some canine oral malignant melanoma (OMM) cases respond to ICIs. To explore biomarkers predictive of survival in dogs with pulmonary metastatic OMM receiving the anti-PD-L1 antibody c4G12 (n = 27), serum concentrations of prostaglandin E2 (PGE(2)), cytokines, chemokines, and growth factors were measured prior to treatment initiation. Among 12 factors tested, PGE(2), interleukin (IL)-12p40, IL-8, monocyte chemotactic protein-1 (MCP-1), and stem cell factor (SCF) were higher in OMM dogs compared to healthy dogs (n = 8). Further, lower baseline serum PGE(2), MCP-1, and vascular endothelial growth factor (VEGF)-A concentrations as well as higher IL-2, IL-12, and SCF concentrations predicted prolonged overall survival. These observations suggest that PGE(2) confers resistance against anti-PD-L1 therapy through immunosuppression and thus is a candidate target for combination therapy. Indeed, PGE(2) suppressed IL-2 and interferon (IFN)-γ production by stimulated canine peripheral blood mononuclear cells (PBMCs), while inhibition of PGE(2) biosynthesis using the COX-2 inhibitor meloxicam in combination with c4G12 enhanced Th1 cytokine production by PBMCs. Thus, serum PGE(2) may be predictive of c4G12 treatment response, and concomitant use of COX-2 inhibitors may enhance ICI antitumor efficacy. |
format | Online Article Text |
id | pubmed-9166720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91667202022-06-05 Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy Maekawa, Naoya Konnai, Satoru Asano, Yumie Sajiki, Yamato Deguchi, Tatsuya Okagawa, Tomohiro Watari, Kei Takeuchi, Hiroto Takagi, Satoshi Hosoya, Kenji Kim, Sangho Ohta, Hiroshi Kato, Yukinari Suzuki, Yasuhiko Murata, Shiro Ohashi, Kazuhiko Sci Rep Article Immune checkpoint inhibitors (ICIs) such as anti-PD-L1 antibodies are widely used to treat human cancers, and growing evidence suggests that ICIs are promising treatments for canine malignancies. However, only some canine oral malignant melanoma (OMM) cases respond to ICIs. To explore biomarkers predictive of survival in dogs with pulmonary metastatic OMM receiving the anti-PD-L1 antibody c4G12 (n = 27), serum concentrations of prostaglandin E2 (PGE(2)), cytokines, chemokines, and growth factors were measured prior to treatment initiation. Among 12 factors tested, PGE(2), interleukin (IL)-12p40, IL-8, monocyte chemotactic protein-1 (MCP-1), and stem cell factor (SCF) were higher in OMM dogs compared to healthy dogs (n = 8). Further, lower baseline serum PGE(2), MCP-1, and vascular endothelial growth factor (VEGF)-A concentrations as well as higher IL-2, IL-12, and SCF concentrations predicted prolonged overall survival. These observations suggest that PGE(2) confers resistance against anti-PD-L1 therapy through immunosuppression and thus is a candidate target for combination therapy. Indeed, PGE(2) suppressed IL-2 and interferon (IFN)-γ production by stimulated canine peripheral blood mononuclear cells (PBMCs), while inhibition of PGE(2) biosynthesis using the COX-2 inhibitor meloxicam in combination with c4G12 enhanced Th1 cytokine production by PBMCs. Thus, serum PGE(2) may be predictive of c4G12 treatment response, and concomitant use of COX-2 inhibitors may enhance ICI antitumor efficacy. Nature Publishing Group UK 2022-06-03 /pmc/articles/PMC9166720/ /pubmed/35665759 http://dx.doi.org/10.1038/s41598-022-13484-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Maekawa, Naoya Konnai, Satoru Asano, Yumie Sajiki, Yamato Deguchi, Tatsuya Okagawa, Tomohiro Watari, Kei Takeuchi, Hiroto Takagi, Satoshi Hosoya, Kenji Kim, Sangho Ohta, Hiroshi Kato, Yukinari Suzuki, Yasuhiko Murata, Shiro Ohashi, Kazuhiko Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title | Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title_full | Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title_fullStr | Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title_full_unstemmed | Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title_short | Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy |
title_sort | exploration of serum biomarkers in dogs with malignant melanoma receiving anti-pd-l1 therapy and potential of cox-2 inhibition for combination therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166720/ https://www.ncbi.nlm.nih.gov/pubmed/35665759 http://dx.doi.org/10.1038/s41598-022-13484-8 |
work_keys_str_mv | AT maekawanaoya explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT konnaisatoru explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT asanoyumie explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT sajikiyamato explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT deguchitatsuya explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT okagawatomohiro explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT watarikei explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT takeuchihiroto explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT takagisatoshi explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT hosoyakenji explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT kimsangho explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT ohtahiroshi explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT katoyukinari explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT suzukiyasuhiko explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT muratashiro explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy AT ohashikazuhiko explorationofserumbiomarkersindogswithmalignantmelanomareceivingantipdl1therapyandpotentialofcox2inhibitionforcombinationtherapy |